enow.com Web Search

  1. Ads

    related to: new drugs for schizophrenia 2023

Search results

  1. Results from the WOW.Com Content Network
  2. This FDA-approved drug promises a new way to treat schizophrenia

    www.aol.com/fda-approved-drug-promises-way...

    About 3.7 million, or 1.8%, of adults in the U.S. have a lifetime history of schizophrenia, according to research published in 2023. The estimate was two to three times higher than previous estimates.

  3. FDA approves 1st new drug for schizophrenia in more ... - AOL

    www.aol.com/fda-approves-1st-drug-schizophrenia...

    The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...

  4. Ulotaront - Wikipedia

    en.wikipedia.org/wiki/Ulotaront

    The Brief Negative Symptom Scale (BNSS) has been used to assess the effect of Ulotaront on the negative symptoms of schizophrenia. [18] In July 2023, the pharmaceutical company behind the drug announced that the drug had failed to outperform placebo in the treatment of acutely psychotic patients with schizophrenia, as measured by the PANSS. [19]

  5. Bristol Myers wins US FDA approval for new type of ...

    www.aol.com/news/us-fda-approves-bristol-myers...

    (Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades. The ...

  6. Xanomeline/trospium chloride - Wikipedia

    en.wikipedia.org/wiki/Xanomeline/trospium_chloride

    Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. [1] It contains xanomeline, a muscarinic agonist; and trospium chloride, a muscarinic antagonist. [1]

  7. Brilaroxazine - Wikipedia

    en.wikipedia.org/wiki/Brilaroxazine

    RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...

  1. Ads

    related to: new drugs for schizophrenia 2023